Contact Information: Contact: Richard Oh Taglich Brothers, Inc. 631-757-1500
Taglich Brothers Initiates Coverage on Cardium Therapeutics, Inc.
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Taglich Brothers, Inc.
| Source: Taglich Brothers, Inc.
NEW YORK, NY--(Marketwire - October 22, 2007) - Taglich Brothers, Inc. announces
it initiated coverage of Cardium Therapeutics, Inc. (AMEX : CXM ).
Cardium Therapeutics, Inc., headquartered in San
Diego, CA, is a biomedical company that is developing regenerative
therapies for the treatment of myocardial ischemia and diabetic foot
ulcers. The company's surface and endovascular temperature modulation
systems, which are already commercialized, have applications in
neurosurgery, cardiac arrest, stroke and central nervous system trauma
cases.
Potentially wide selling products are being developed or commercialized
with a view to offering them for acquisition to large pharmaceutical or
biomedical firms. The lead pipeline product, Generx, aims to reverse
microvascular ischemia by promoting angiogenesis. A second pipeline
product, Excellarate, is a wound care product developed to heal diabetic
foot ulcers that are not responsive to standard treatments. Temperature
modulation systems, a product line already commercialized, are helpful in
treating neurosurgery, cardiac arrest, stroke and central nervous system
trauma patients.
The complete 20-page report is available at www.taglichbrothers.com.
Taglich Brothers, Inc. is a
full-service broker dealer focused exclusively on microcap companies. The
Company defines the microcap segment of the equity market as companies with
less than $250 million in market capitalization. Taglich Brothers currently
offers institutional and retail brokerage services, investment banking and
comprehensive research coverage to the investment community.
We do not undertake to advise you as to changes in figures or our views.
This is not a solicitation of any order to buy or sell. Taglich Brothers,
Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a
market maker and does not sell to or buy from customers on a principal
basis. The above statement is the opinion of Taglich Brothers, Inc. and is
not a guarantee that the target price for the stock will be met or that
predicted business results for the company will occur. There may be
instances when fundamental, technical and quantitative opinions contained
in this report are not in concert. We, our affiliates, any officer,
director or stockholder or any member of their families may from time to
time purchase or sell any of the above-mentioned or related securities.
Analysts and members of the Research Department are prohibited from buying
or selling securities issued by the companies that Taglich Brothers, Inc.
has a research relationship with, except if ownership of such securities
was prior to the start of such relationship, then an Analyst or member of
the Research Department may sell such securities after obtaining expressed
written permission from the Director of Research. As of the date of this
report no Taglich Brothers, Inc. employees had a position in the stock of
the Company mentioned in this report: All research issued by Taglich
Brothers, Inc. is based on public information. The company paid a $5,000
(USD) engagement fee in August, 2007 and will, commencing upon distribution
of our initial report, pay $1,750 (USD) per month for the creation and
dissemination of research reports.
For further information and Taglich Brothers, Inc. ownership data please
refer to each individual report.